Renovorx highlights recent presentation of clinical data abstract at the 2024 society of interventional radiology annual scientific meeting

Los altos, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today highlights a presentation of a clinical data abstract at the recent 2024 society of interventional radiology (sir) annual scientific meeting, held march 23-27, 2024 in salt lake city, utah. clinical data was presented by david sperling, md, associate professor of ra.
RNXT Ratings Summary
RNXT Quant Ranking